Tag: Bluebird Bio acquisition
Challenges at FDA & bluebird Bio Sale: What You Need to Know
This morning, Praxis Precision Medicine announced that an independent data monitoring committee recommended discontinuing a Phase 3 study involving its experimental treatment for essential...
Bluebird Bio Sold to Carlyle, SK Capital for Under $30M
Bluebird Bio, a once-promising biotech company, made headlines recently with its decision to sell itself and its portfolio of gene therapies to investment firms...
BREAKING NEWS
NYU School of Global Public Health Wins STAT Madness Vote
In a spirited celebration of scientific discovery, the recent STAT Breakthrough Summit East in Manhattan hosted a unique event that drew parallels to the...
